沃森生物(300142.SZ):ACYW135羣腦膜炎球菌多糖結合疫苗獲得Ⅲ期臨牀試驗倫理審查意見書
格隆匯10月11日丨沃森生物(300142.SZ)公佈,公司和子公司玉溪沃森生物技術有限公司自主研發的ACYW135羣腦膜炎球菌多糖結合疫苗(簡稱“四價流腦結合疫苗”)於近日收到了由廣西倫理審查委員會簽發的開展Ⅲ期臨牀試驗的倫理審查意見書,標誌着該疫苗進入Ⅲ期臨牀試驗階段。審查意見為:經審查討論,作出“同意”的審查意見,相關資料的修改符合倫理要求,同意在本項目中使用。
公司四價流腦結合疫苗於2012年9月申報臨牀研究,並於2015年1月獲得了《藥物臨牀試驗批件》,開始進入臨牀研究階段。本疫苗屬於預防用生物製品,適用於嬰幼兒及以上人羣預防A羣、C羣、Y羣和W135羣腦膜炎球菌感染引起的流行性腦脊髓膜炎等腦膜炎球菌疾病。目前,全球四價流腦結合疫苗的生產廠家包括賽諾菲-巴斯德、GSK和輝瑞,國內暫無本土企業有該產品生產上市。
公司在流腦疫苗領域有較大的優勢,目前,公司已有3個流腦疫苗產品(包括A羣C羣腦膜炎球菌多糖疫苗、A羣C羣腦膜炎球菌多糖結合疫苗和ACYW135羣腦膜炎球菌多糖疫苗)上市銷售。本次獲得四價流腦結合疫苗Ⅲ期臨牀試驗倫理審查意見書後,公司將按照國家臨牀試驗的有關規定儘快推進該疫苗的Ⅲ期臨牀試驗,爭取產品早日上市,進一步豐富公司流腦疫苗產品線,提升產品的競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.